AMAG acquires Cord Blood Registry for $700mm
Executive Summary
AMAG Pharmaceuticals Inc. acquired Cord Blood Registry Inc. (CBR), a private newborn stem cell banking company, for $700mm in cash, or approximately 5.6x CBR's 2014 pro form revenue ($126mm) and 15.6x its EBIDTA ($45mm). AMAG funded the transaction via a concurrent $800mm debt offering.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice